

Philippe Devillier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/504420/publications.pdf>

Version: 2024-02-01

124
papers

5,345
citations

57758

44
h-index

98798

67
g-index

138
all docs

138
docs citations

138
times ranked

4852
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of the Control of Allergic Rhinitis and Asthma Test (CARAT) using MASK-air. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 343-345.e2.	3.8	11
2	Development and validation of combined symptom& medication scores for allergic rhinitis*. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2147-2162.	5.7	32
3	Determining the minimal important differences in the RQLQ score with grass and tree allergy immunotherapy versus placebo in adults with moderate& severe allergy. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1843-1851.	5.7	5
4	Allergen immunotherapy in MASK&air users in real&life: Results of a Bayesian mixed&effects model. Clinical and Translational Allergy, 2022, 12, e12128.	3.2	9
5	Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK&air^{Â®} real&world data. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2699-2711.	5.7	17
6	Biomedical detection dogs for the identification of SARS-CoV-2 infections from axillary sweat and breath samples [*]. Journal of Breath Research, 2022, 16, 037101.	3.0	14
7	Position paper of the French Society of Respiratory Diseases regarding pharmacological treatment optimization for stable COPD in 2021. Respiratory Medicine and Research, 2022, 81, 100889.	0.6	0
8	Comparison of rhinitis treatments using <sc>MASK</sc>&airÂ® data and considering the minimal important difference. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 3002-3014.	5.7	8
9	Clinical relevance of the relaxant effects of roflumilast on human bronchus: potentiation by a long&acting beta&agonist. Fundamental and Clinical Pharmacology, 2021, 35, 725-731.	1.9	4
10	Placebo effects in allergen immunotherapy& An EAACI Task Force Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 629-647.	5.7	31
11	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 168-190.	5.7	46
12	Metabolomics of exhaled breath in critically ill COVID-19 patients: A pilot study. EBioMedicine, 2021, 63, 103154.	6.1	143
13	Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1041-1052.	5.7	38
14	Heterogeneity of the pharmacologic treatment of allergic rhinitis in Europe based on MIDAS and OTCims platforms. Clinical and Experimental Allergy, 2021, 51, 1033-1045.	2.9	8
15	Technical standards in allergen exposure chambers worldwide & an EAACI Task Force Report. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3589-3612.	5.7	23
16	Effects of allergen immunotherapy in the MASK&air study: a proof&of&concept analysis. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3212-3214.	5.7	14
17	Adiponectin Inhibits the Production of TNF-Î±, IL-6 and Chemokines by Human Lung Macrophages. Frontiers in Pharmacology, 2021, 12, 718929.	3.5	17
18	Validity, reliability, and responsiveness of daily monitoring visual analog scales in MASK&airÂ®. Clinical and Translational Allergy, 2021, 11, e12062.	3.2	31

#	ARTICLE	IF	CITATIONS
19	Evaluating response to biologics in severe asthma: Precision or guesswork?. <i>Respiratory Medicine and Research</i> , 2021, 80, 100813.	0.6	1
20	The Role of Toll-Like Receptors in the Production of Cytokines by Human Lung Macrophages. <i>Journal of Innate Immunity</i> , 2020, 12, 63-73.	3.8	73
21	Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 70-80.e3.	2.9	272
22	Efficacy of immunoglobulin replacement therapy and azithromycin in severe asthma with antibody deficiency. <i>Allergology International</i> , 2020, 69, 215-222.	3.3	8
23	Clinical Relevance of the Anti-inflammatory Effects of Roflumilast on Human Bronchus: Potentiation by a Long-Acting Beta-2-Agonist. <i>Frontiers in Pharmacology</i> , 2020, 11, 598702.	3.5	4
24	Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study. <i>Clinical and Translational Allergy</i> , 2020, 10, 62.	3.2	34
25	Granulomatous Lymphocytic Interstitial Lung Disease (GLILD) in Common Variable Immuno Deficiency (CVID). , 2020, , .		0
26	Chloroquine Inhibits the Release of Inflammatory Cytokines by Human Lung Explants. <i>Clinical Infectious Diseases</i> , 2020, 71, 2265-2268.	5.8	9
27	Allergen immunotherapy: what is the added value of real-world evidence from retrospective claims database studies?. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 445-452.	2.5	20
28	Contrasting Effects of Adipokines on the Cytokine Production by Primary Human Bronchial Epithelial Cells: Inhibitory Effects of Adiponectin. <i>Frontiers in Pharmacology</i> , 2020, 11, 56.	3.5	25
29	Prioritising outcomes for evaluating eosinophil-guided corticosteroid therapy among patients with acute COPD exacerbations requiring hospitalisation: a Delphi consensus study. <i>BMJ Open</i> , 2020, 10, e035811.	1.9	5
30	How can we minimise the use of regular oral corticosteroids in asthma?. <i>European Respiratory Review</i> , 2020, 29, 190085.	7.1	34
31	Correlation between work impairment, scores of rhinitis severity and asthma using the MASK ^{air} App. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1672-1688.	5.7	32
32	Metabolic reprogramming of LPS-stimulated human lung macrophages involves tryptophan metabolism and the aspartate-arginosuccinate shunt. <i>PLoS ONE</i> , 2020, 15, e0230813.	2.5	18
33	Clinical efficacy of sublingual immunotherapy tablets for allergic rhinitis is unlikely to be derived from <i>in vitro</i> allergen-release data. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 921-928.	3.0	7
34	Bitter Taste Receptors (TAS2Rs) in Human Lung Macrophages: Receptor Expression and Inhibitory Effects of TAS2R Agonists. <i>Frontiers in Physiology</i> , 2019, 10, 1267.	2.8	51
35	Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. <i>Clinical and Translational Allergy</i> , 2019, 9, 44.	3.2	87
36	Dual versus triple therapy in patients hospitalized for COPD in France: a claims data study. <i>International Journal of COPD</i> , 2019, Volume 14, 1839-1854.	2.3	8

#	ARTICLE	IF	CITATIONS
37	Patient preference for chronic obstructive pulmonary disease (COPD) treatment inhalers: a discrete choice experiment in France. <i>Current Medical Research and Opinion</i> , 2019, 35, 785-792.	1.9	13
38	Determination of the minimally important difference in a nasal symptom score in house dust mite allergy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2191-2198.	5.7	10
39	Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 135-143.e6.	2.9	101
40	Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma. <i>Clinical and Translational Allergy</i> , 2019, 9, 16.	3.2	81
41	Google Trends and pollen concentrations in allergy and airway diseases in France. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1910-1919.	5.7	17
42	<sc>ARIA</sc> pharmacy 2018 – Allergic rhinitis care pathways for community pharmacy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1219-1236.	5.7	52
43	Immunotherapy with grass pollen tablets reduces medication dispensing for allergic rhinitis and asthma: A retrospective database study in France. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1317-1326.	5.7	47
44	Adherence to treatment in allergic rhinitis using mobile technology. The <sc>MASK</sc> Study. <i>Clinical and Experimental Allergy</i> , 2019, 49, 442-460.	2.9	73
45	<sc>CCR</sc>10⁺ <sc>ILC</sc>2s with <sc>ILC</sc>1-like properties exhibit a protective function in severe allergic asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 933-943.	5.7	22
46	Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 864-879.	2.9	103
47	Gamma globulin replacement therapy in uncontrolled, severe asthma associated with humoral immunodeficiency: A series of five case reports. <i>Journal of Asthma</i> , 2019, 56, 79-83.	1.7	1
48	Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the <sc>MASK</sc> study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1622-1631.	5.7	69
49	Treatment of allergic rhinitis using mobile technology with real-world data: The <sc>MASK</sc> observational pilot study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1763-1774.	5.7	94
50	Comparison of the in vitro pharmacological profiles of long-acting muscarinic antagonists in human bronchus. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 49, 46-53.	2.6	17
51	Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: A retrospective, real-world database analysis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 165-177.	5.7	135
52	The Allergic Rhinitis and its Impact on Asthma (ARIA) score of allergic rhinitis using mobile technology correlates with quality of life: The MASK study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 505-510.	5.7	77
53	MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. <i>Clinical and Translational Allergy</i> , 2018, 8, 45.	3.2	104
54	Home spirometry in bronchiolitis obliterans after allogeneic haematopoietic cell transplant. <i>European Respiratory Journal</i> , 2018, 52, 1702328.	6.7	14

#	ARTICLE	IF	CITATIONS
55	Geolocation with respect to personal privacy for the Allergy Diary app - a MASK study. World Allergy Organization Journal, 2018, 11, 15.	3.5	33
56	Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β_2 -agonists (ICS/LABA) in patients with uncontrolled asthma: An open-label, randomized, controlled trial. Respiratory Medicine, 2018, 141, 111-120.	2.9	11
57	Comparison of scores associating symptoms and rescue medication use for evaluating the efficacy of allergy immunotherapy in seasonal allergic rhinoconjunctivitis: results from five trials. Clinical and Experimental Allergy, 2017, 47, 254-263.	2.9	7
58	Pilot study of mobile phone technology in allergic rhinitis in European countries: the MASK-rhinitis study. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 857-865.	5.7	93
59	Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future – an EAACI Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1035-1042.	5.7	85
60	Work productivity in rhinitis using cell phones: The MASK pilot study. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1475-1484.	5.7	69
61	Sialylated Fetuin-A as a candidate predictive biomarker for successful grass pollen allergen immunotherapy. Journal of Allergy and Clinical Immunology, 2017, 140, 759-770.e13.	2.9	11
62	Grass pollen sublingual immunotherapy tablets provide long-term relief of grass pollen-associated allergic rhinitis and reduce the risk of asthma: findings from a retrospective, real-world database subanalysis. Expert Review of Clinical Immunology, 2017, 13, 1199-1206.	3.0	24
63	In smokers, Sonic hedgehog modulates pulmonary endothelial function through vascular endothelial growth factor. Respiratory Research, 2017, 18, 102.	3.6	4
64	Human lung and monocyte-derived macrophages differ with regard to the effects of β_2 -adrenoceptor agonists on cytokine release. Respiratory Research, 2017, 18, 126.	3.6	18
65	Metabolomics in the Diagnosis and Pharmacotherapy of Lung Diseases. Current Pharmaceutical Design, 2017, 23, 2050-2059.	1.9	14
66	Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies. Clinical and Translational Allergy, 2016, 6, 41.	3.2	24
67	ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clinical and Translational Allergy, 2016, 6, 47.	3.2	121
68	House dust mite sublingual immunotherapy is safe in patients with mild-to-moderate, persistent asthma: a clinical trial. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 249-257.	5.7	34
69	Methodological aspects of a meta-analysis of grass pollen allergen sublingual immunotherapy tablets. Journal of Allergy and Clinical Immunology, 2016, 138, 314-315.e4.	2.9	7
70	Rhinite allergique: Dymista®, une alternative thérapeutique. Revue Française D'allergologie, 2016, 56, 462-470.	0.2	1
71	300 IR HDM tablet: a sublingual immunotherapy tablet for the treatment of house dust mite-associated allergic rhinitis. Expert Review of Clinical Immunology, 2016, 12, 1141-1151.	3.0	12
72	Prevalence and reversibility of lung hyperinflation in adult asthmatics with poorly controlled disease or significant dyspnea. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 108-114.	5.7	13

#	ARTICLE	IF	CITATIONS
73	In allergic rhinitis, work, classroom and activity impairments are weakly related to other outcome measures. <i>Clinical and Experimental Allergy</i> , 2016, 46, 1456-1464.	2.9	31
74	Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5). <i>Clinical and Translational Allergy</i> , 2016, 6, 29.	3.2	47
75	Limited treatment adaptation despite poor asthma control in asthma patients treated with inhaled corticosteroids. <i>Journal of Asthma</i> , 2016, 53, 76-85.	1.7	9
76	Efficacy and safety of sublingual tablets of house dust mite allergen extracts: Results of a dose-ranging study in an environmental exposure chamber. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 451-458.e5.	2.9	53
77	Comparison of outcome measures in allergic rhinitis in children, adolescents and adults. <i>Pediatric Allergy and Immunology</i> , 2016, 27, 375-381.	2.6	30
78	Roflumilast n-oxide associated with PGE2 prevents the neutrophil elastase-induced production of chemokines by epithelial cells. <i>International Immunopharmacology</i> , 2016, 30, 1-8.	3.8	7
79	MACVIA-ARIA Sentinel Network for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 1372-1392.	5.7	160
80	The long-acting β_2 -adrenoceptor agonist olodaterol attenuates pulmonary inflammation. <i>British Journal of Pharmacology</i> , 2015, 172, 3537-3547.	5.4	15
81	15-Lipoxygenases regulate the production of chemokines in human lung macrophages. <i>British Journal of Pharmacology</i> , 2015, 172, 4319-4330.	5.4	45
82	V0162 a new long-acting bronchodilator for treatment of chronic obstructive lung diseases: preclinical and clinical results. <i>Respiratory Research</i> , 2015, 16, 68.	3.6	9
83	Is arginase a potential drug target in tobacco-induced pulmonary endothelial dysfunction?. <i>Respiratory Research</i> , 2015, 16, 46.	3.6	10
84	Clinical Relevance of Cluster Analysis in Phenotyping Allergic Rhinitis in a Real-Life Study. <i>International Archives of Allergy and Immunology</i> , 2015, 166, 231-240.	2.1	24
85	Characterization of V0162, a new long-acting antagonist at human M3 muscarinic acetylcholine receptors. <i>Pharmacological Research</i> , 2015, 100, 117-126.	7.1	11
86	Allergic rhinitis treatment with sublingual immunotherapy. <i>Journal of Pediatrics</i> , 2015, 167, 1169-1172.	1.8	0
87	The minimally important difference in the Rhinoconjunctivitis Total Symptom Score in grass-pollen-induced allergic rhinoconjunctivitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 1689-1695.	5.7	35
88	Cannabinoids inhibit cholinergic contraction in human airways through prejunctional CB_1 receptors. <i>British Journal of Pharmacology</i> , 2014, 171, 2767-2777.	5.4	42
89	House dust mite sublingual immunotherapy is safe and appears to be effective in moderate, persistent asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 1181-1188.	5.7	68
90	A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis. <i>BMC Medicine</i> , 2014, 12, 71.	5.5	90

#	ARTICLE	IF	CITATIONS
91	Integrated care pathways for airway diseases (AIRWAYS-ICPs). <i>European Respiratory Journal</i> , 2014, 44, 304-323.	6.7	154
92	The expression and relaxant effect of bitter taste receptors in human bronchi. <i>Respiratory Research</i> , 2013, 14, 134.	3.6	82
93	Impact of Allergic Rhinitis Symptoms on Quality of Life in Primary Care. <i>International Archives of Allergy and Immunology</i> , 2013, 160, 393-400.	2.1	159
94	Small airway impairment in moderate to severe asthmatics without significant proximal airway obstruction. <i>Respiratory Medicine</i> , 2013, 107, 1667-1674.	2.9	65
95	TNF- α -induced CXCL8 production by A549 cells: Involvement of the non-neuronal cholinergic system. <i>Pharmacological Research</i> , 2013, 68, 16-23.	7.1	16
96	Visual analogue scale in patients treated for allergic rhinitis: an observational prospective study in primary care. <i>Clinical and Experimental Allergy</i> , 2013, 43, 881-888.	2.9	135
97	Roflumilast Inhibits Lipopolysaccharide-Induced Tumor Necrosis Factor- α and Chemokine Production by Human Lung Parenchyma. <i>PLoS ONE</i> , 2013, 8, e74640.	2.5	24
98	Prostanoid Receptors Involved in Regulation of the Beating Rate of Neonatal Rat Cardiomyocytes. <i>PLoS ONE</i> , 2012, 7, e45273.	2.5	6
99	Can β_2 -adrenoceptor agonists, anticholinergic drugs, and theophylline contribute to the control of pulmonary inflammation and emphysema in COPD?. <i>Fundamental and Clinical Pharmacology</i> , 2012, 26, 118-134.	1.9	9
100	Roflumilast inhibits the release of chemokines and TNF- α from human lung macrophages stimulated with lipopolysaccharide. <i>British Journal of Pharmacology</i> , 2012, 165, 1877-1890.	5.4	61
101	Analysis of allergen immunotherapy studies shows increased clinical efficacy in highly symptomatic patients. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012, 67, 321-327.	5.7	51
102	Response by P. Devillier, on behalf of the authors. <i>Clinical and Experimental Allergy</i> , 2012, 42, 806-806.	2.9	0
103	Expression and proliferative effect of hemokinin-1 in human B-cells. <i>Peptides</i> , 2011, 32, 1027-1034.	2.4	13
104	The allergen challenge chamber: a valuable tool for optimizing the clinical development of pollen immunotherapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2011, 66, 163-169.	5.7	49
105	How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA2LEN statement. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2011, 66, 765-774.	5.7	67
106	The average Adjusted Symptom Score, a new primary efficacy endpoint for specific allergen immunotherapy trials. <i>Clinical and Experimental Allergy</i> , 2011, 41, 1282-1288.	2.9	51
107	Update on the roles of distal airways in COPD. <i>European Respiratory Review</i> , 2011, 20, 007-22.	7.1	70
108	Tobacco-associated pulmonary vascular dysfunction in smokers: role of the ET-1 pathway. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2011, 300, L831-L839.	2.9	11

#	ARTICLE	IF	CITATIONS
109	The role of adenosine receptors in regulating production of tumour necrosis factor α and chemokines by human lung macrophages. <i>British Journal of Pharmacology</i> , 2010, 159, 1304-1311.	5.4	33
110	Pharmacological Characterization of Olodaterol, a Novel Inhaled β_2 -Adrenoceptor Agonist Exerting a 24-Hour-Long Duration of Action in Preclinical Models. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 334, 53-62.	2.5	106
111	Tiotropium reduction of lung inflammation in a model of chronic gastro-oesophageal reflux. <i>European Respiratory Journal</i> , 2010, 35, 1370-1376.	6.7	34
112	Expression and function of human hemokinin-1 in human and guinea pig airways. <i>Respiratory Research</i> , 2010, 11, 139.	3.6	20
113	Update on the roles of distal airways in asthma. <i>European Respiratory Review</i> , 2009, 18, 80-95.	7.1	61
114	Desloratadine relieves nasal congestion and improves quality of life in persistent allergic rhinitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2009, 64, 1663-1670.	5.7	23
115	Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 124, 471-477.e1.	2.9	174
116	Clinical Pharmacokinetics and Pharmacodynamics of Desloratadine, Fexofenadine and Levocetirizine. <i>Clinical Pharmacokinetics</i> , 2008, 47, 217-230.	3.5	64
117	Muscarinic receptors involved in airway vascular leakage induced by experimental gastro-oesophageal reflux. <i>Life Sciences</i> , 2008, 82, 949-955.	4.3	18
118	Letter to the editor. <i>Clinical Therapeutics</i> , 2007, 29, 2774-2775.	2.5	0
119	Desloratadine improves quality of life and symptom severity in patients with allergic rhinitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2007, 62, 1331-1334.	5.7	38
120	Inhibition of the histamine-induced weal and flare response: a valid surrogate measure for antihistamine clinical efficacy?. <i>Clinical and Experimental Allergy</i> , 2007, 37, 400-414.	2.9	24
121	Comparing the new antihistamines: the role of pharmacological parameters. <i>Clinical and Experimental Allergy</i> , 2006, 36, 5-7.	2.9	13
122	Role of the N-terminal arginine in the histamine-releasing activity of substance P, bradykinin and related peptides. <i>European Journal of Pharmacology</i> , 1989, 168, 53-60.	3.5	80
123	Characterisation of enkephalinase (EC 3.4.24.11) activity on various leukemic cells expressing the common acute lymphocytic leukemia antigen (CALLA). <i>FEBS Letters</i> , 1989, 248, 123-126.	2.8	7
124	Peptides and histamine release from rat peritoneal mast cells. <i>European Journal of Pharmacology</i> , 1985, 117, 89-96.	3.5	103